Human Immunodeficiency Virus Protease Inhibitors
- 1 January 1999
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 19 (1) , 35-59
- https://doi.org/10.1592/phco.19.1.35.30513
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Antiretroviral Therapy for HIV Infection in 1998JAMA, 1998
- A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic MillimeterNew England Journal of Medicine, 1996
- Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic MillimeterNew England Journal of Medicine, 1996
- Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individualsThe Lancet, 1996
- Therapy for Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1993
- Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agentsAntimicrobial Agents and Chemotherapy, 1993
- The HIV-1 Protease as a Therapeutic Target for AIDSAIDS Research and Human Retroviruses, 1992
- Active human immunodeficiency virus protease is required for viral infectivity.Proceedings of the National Academy of Sciences, 1988
- Isolation of Human T-Cell Leukemia Virus in Acquired Immune Deficiency Syndrome (AIDS)Science, 1983
- Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)Science, 1983